diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy. AI diagnostics company IDx has signed an exclusivity agreement with ophthalmic device maker the US Food and Drug Administration to scale AI-based diagnostic solutions in the N.J. . The deal makes IDx the only autonomous AI firm able to sell products with the Topcon the Topcon NW400 robotic camera, which detects diabetic retinopathy in fundus images. IDx’s AI system, IDx-DR, was approved by Topcon Oct. 22, 2018 after a clinical trial. Operators with minimal training produced a result 96% of the time, capturing images using the Topcon NW400 , which the IDx-DR system needed to make a disease assessment.
AI diagnostics company IDx has signed an exclusivity agreement with ophthalmic device maker the US Food and Drug Administration to scale AI-based diagnostic solutions in the N.J. . The deal makes IDx the only autonomous AI firm able to sell products with the Topcon the Topcon NW400 robotic camera, which detects diabetic retinopathy in fundus images. IDx’s AI system, IDx-DR, was approved by Topcon Oct. 22, 2018 after a clinical trial. Operators with minimal training produced a result 96% of the time, capturing images using the Topcon NW400 , which the IDx-DR system needed to make a disease assessment.